

## Harmony P Garges, MD MPH




- / Chief Medical Officer and Head of Global Medical for ViiV Healthcare, the only pharmaceutical company 100% focused on HIV.
- / Accountable for all aspects of human safety and medical governance for the company and leads the medical affairs, pharmacovigilance and regulatory functions
- / Physician with 20+ year expertise in **pediatrics** and infectious diseases
- / 15+ years of experience within the pharmaceutical industry with leadership experience across R&D, pharmacovigilance, and medical affairs



#### Our commitment to ESG





**Environmental** 



Social



Governance



#### Decades of progress have changed the HIV epidemic



CENTERS FOR DISEASE CONTROL

MORBIDITY AND MORTALITY WEEKLY REPORT

June 5, 1981 / Vol. 30 / No. 21

Epidemiologic Notes and Reports
Dengue Type 4 Infections in U.S. Travelers to the Caribbean

250 Pneumocystis Pneumonia – Los An-

Current Trends

252 Measles — United States, First 20 Weeks


253 Risk-Factor-Prevalence Survey — Utah 259 Surveillance of Childhood Lead Poisoning — United States International Notes

261 Quarantine Measures

Epidemiologic Notes and Reports


#### Pneumocystis Pneumonia - Los Angeles

In the period October 1980-May 1981, 5 young men, all active homosexuals, were treated for biopsy-confirmed *Pneumocystis carinii* pneumonia at 3 different hospitals in Los Angeles, California. Two of the patients died. All 5 patients had laboratory-confirmed previous or current systematically infection, and candidal mucosal









### But the HIV epidemic is not over

## 37.9 million people are eligible for antiretroviral therapy

Under the 'Treat All' approach advocated by WHO's guidelines<sup>1,2</sup>

#### **COVID-19 impacting progress**

significant reduction in HIV testing and switch through the pandemic<sup>3</sup>

## Pre-exposure prophylaxis (PrEP) is underutilised

even in developed countries like the US, where only 25% of those who could benefit from PrEP are taking it<sup>5</sup>

#### **Continued HIV transmission**

1.5 million new cases each year<sup>3</sup>

#### Access to treatment is crucial

But only ~73% of all PLHIV<sup>4</sup> are accessing treatment<sup>3</sup>

## Need for new approaches in treatment

One in three are not virally suppressed<sup>3</sup>

Amilcar Living with HIV Portugal



1. Global Health Observatory (GHO) data https://www.who.int/gho/hiv/en/): http://apps.who.int/iris/bitstream/10665/208825/1/978 9241549684\_eng.pdf?ua. (Online) Last accessed Mar'20 2.. WHO Prevent HIV, Test and Treat All 2016: http://apps.who.int/iris/bitstream/10665/251713/1/WHO-HIV-2016.24-eng.pdf?ua=1. (Online) Last accessed Jan '20. 3.UNAIDS Global HIV Statistics factsheet, updated 2021 4. People living with HIV 5. U.S. Department of Health & Human Services. AHEAD – America's HIV Epidemic Analysis Dashboard. Data PrEP Coverage. https://ahead.hiv.gov/data/prep-coverage. Accessed November 2021.

#### HIV treatment and prevention are about more than medicine



# Improving health disparities



#### The report:



**Provides the clear case** for why action is needed



Identifies stakeholders who can combat disparities



Brings forth the actions that can be taken to address disparities



Clinical Trial Diversity
Task Force







#### ViiV Healthcare – focused on ending HIV and AIDS





Our mission is to leave no person living with HIV behind.



Leaders and disruptors in innovation



Focused and agile, backed by scale of GSK



Built on novel collaborations and powerful partnerships



Strong commitment to communities

2009

GSK and Pfizer<sup>1</sup> created a joint venture dedicated to HIV 2012

Shionogi<sup>2</sup> became partner and shareholder

2013

First dolutegravir launch in the US

2016

Acquired BMS<sup>3</sup> HIV pipeline and discovery assets

2019

Launched Dovato

2020

Launched *Rukobia*, first attachment inhibitor

2021

Launched *Cabenuva*, first long-acting injectable. Strengthened pipeline with Halozyme<sup>4</sup> and Shionogi collaborations


Our commitment to paediatrics

Through our scientific research, innovative partnerships and local community work, we are addressing gaps in paediatric HIV treatment and accelerating access to medicines for infants and children around the world.



#### Our commitment to access





Making our medicines as widely available to patients regardless of income or where they live



Taking an innovative, responsible and, above all, sustainable approach







Alignment with the global HIV response and agenda set by UNAIDS and the Sustainable Development Goals (SDGs)

#### Our commitment to community

100+ projects selected for ViiV COVID-19 Emergency Response Fund



Eddie Living with HIV Florida, US



# To leave no person living with HIV behind

Visit ViiVHealthcare.com to learn more

Yulia, Living with HIV, St Petersburg, Russia

